Last reviewed · How we verify
Risperidone and placebo comparator
Risperidone and placebo comparator is a atypical antipsychotic Small molecule drug developed by University of Alabama at Birmingham. It is currently in Phase 3 development for Schizophrenia, Bipolar disorder.
Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.
Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. Used for Schizophrenia, Bipolar disorder.
At a glance
| Generic name | Risperidone and placebo comparator |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | atypical antipsychotic |
| Target | D2 receptor, 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This dual action helps to reduce symptoms of psychosis, such as hallucinations and delusions, by blocking the effects of dopamine and serotonin in the brain. Risperidone also has some effect on other neurotransmitter systems, including norepinephrine and acetylcholine.
Approved indications
- Schizophrenia
- Bipolar disorder
Common side effects
- Weight gain
- Dizziness
- Headache
- Somnolence
- Nausea
Key clinical trials
- Subjective Experience Following Psilocybin (PHASE2)
- Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (PHASE2)
- Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use (PHASE2)
- Safety and Efficacy of MP-214 in Patients With Schizophrenia (PHASE2, PHASE3)
- A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (PHASE3)
- the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period. (NA)
- Does Psilocybin Require Psychedelic Effects to Treat Depression? (PHASE2)
- A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone and placebo comparator CI brief — competitive landscape report
- Risperidone and placebo comparator updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI
Frequently asked questions about Risperidone and placebo comparator
What is Risperidone and placebo comparator?
How does Risperidone and placebo comparator work?
What is Risperidone and placebo comparator used for?
Who makes Risperidone and placebo comparator?
What drug class is Risperidone and placebo comparator in?
What development phase is Risperidone and placebo comparator in?
What are the side effects of Risperidone and placebo comparator?
What does Risperidone and placebo comparator target?
Related
- Drug class: All atypical antipsychotic drugs
- Target: All drugs targeting D2 receptor, 5-HT2A receptor
- Manufacturer: University of Alabama at Birmingham — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar disorder
- Compare: Risperidone and placebo comparator vs similar drugs
- Pricing: Risperidone and placebo comparator cost, discount & access